HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

cycletanide (cicletanine)

Subscribe to New Research on cycletanide

Also Known As:

cicletanine; 1,3-dihydro-6-methyl-7-hydroxy-3-(4-chlorophenyl)furo(3,4-d)pyridine; BN 1270; BN-1270; Beaufour brand of cicletanine hydrochloride; Ipsen brand of cicletanine hydrochloride; Justar; Tenstaten; cicletanide; cicletanine hydrochloride; Cycletanide

Networked: 86 relevant articles (8 outcomes, 20 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Pyridines: 41
    - cycletanide: 86

Experts

1.	Droy-Lefaix, M T: 3 articles (11/2004 - 02/2000)
2.	Rockey, Don C: 1 article (07/2013)
3.	Liu, Songling: 1 article (07/2013)
4.	Wagner, Frank: 1 article (04/2012)
5.	Mitta, Shabri: 1 article (04/2012)
6.	Beals, Chan: 1 article (04/2012)
7.	Carey, Robert M: 1 article (04/2012)
8.	Malice, Marie-Pierre: 1 article (04/2012)
9.	De Lepeleire, Inge: 1 article (04/2012)
10.	Wiegert, Erol: 1 article (04/2012)

Related Diseases

1.	Hypertension (High Blood Pressure) 11/01/1989 - "thus, cicletanine, an antihypertensive drug derived from furopyridine, proved to be devoid of adverse effects on glycoregulation and clinically effective on hypertension." 11/01/1989 - "The purpose of this study was to evaluate the effects of cicletanine, a synthetic antihypertensive drug, on the progress of genetic hypertension. " 08/01/1989 - "Although the exact mechanisms of the observed changes in arterial mechanics remain unclear, this study showed that in experimental hypertension cicletanine can affect distensibility of large arteries independently of significant changes in BP." 01/01/1988 - "A further 12-week study was performed in 40 patients with mild to moderate essential hypertension, commencing with a daily dose of cicletanine (50 mg) and increasing the dosage if necessary to 100 mg and 200 mg daily after 4 and 8 weeks, respectively. " 01/01/1988 - "A double-blind multicentre study was performed initially to assess the effect of 4 weeks' treatment of cicletanine in daily doses of 12.5, 25, 50 and 100 mg, for the treatment of 60 patients with mild to moderate essential hypertension. "
2.	Ischemia 02/01/1992 - "In the concentration range of 3 x 10(-5)-10(-4) M, cicletanine improved AF either in ischemia or during reperfusion, whereas 2 x 10(-4) M had no such effect. " 01/01/1999 - "The aim of this study was to assess the effect of cicletanine, an antihypertensive compound in humans, which has been reported to have cardioprotective effect under an ischemia-reperfusion process, on Na+-H+ exchanger activity in ventricular cardiomyocytes isolated from chick embryo. " 02/01/1990 - "Isolated hearts from normotensive (NT) and spontaneously hypertensive (SH) rats, subjected to normothermic global ischemia, were used to study whether cicletanine (a new antihypertensive drug) treatment exerts an antiarrhythmic effect against reperfusion-induced arrhythmias. " 02/01/1992 - "Cicletanine improves myocardial function deteriorated by ischemia/reperfusion in isolated working rat hearts." 04/01/1991 - "Isolated hearts, excised from spontaneously hypertensive male rats treated orally with cicletanine, a new furopyridine anti-hypertensive drug, were subjected to 30 min of global ischemia followed by 10 min of reperfusion. "
3.	Ventricular Tachycardia 01/01/1988 - "Since cicletanine-treated dogs had reduced mean ST segment elevation at 3 min post-occlusion, lower incidence of early post-occlusion (0-10 min) sustained ventricular tachycardia, and increased endogenous production of prostacyclin, and the latter was inversely correlated with the level of ST segment elevation, it is concluded that such favourable effects on the ischaemic myocardium were contributory to the improved outcome in these experiments. " 04/01/1991 - "After 30 min of global ischemia, the incidence (total) of ventricular fibrillation (VF) and ventricular tachycardia (VT) was reduced by 2-week pretreatment of the rats with 30 and 100 mg/kg of cicletanine (VF, 33% at 30 mg/kg and 25% at 100 mg/kg vs. 91% in untreated rats; VT, 42% at 30 mg/kg and 42% at 100 mg/kg vs. 100% in untreated rats), while lower doses of cicletanine (3 and 10 mg/kg) failed to reduce the incidence of reperfusion-induced rhythm disturbances. " 02/01/1990 - "Using the optimal doses of cicletanine (30 and 100 mg/kg orally for 14 days), the incidence of reperfusion-induced ventricular fibrillation (VF) and ventricular tachycardia (VT) was reduced from their control values of 91 and 100% (after 30 min of ischemia) to 41 (p less than 0.05), 50 (p less than 0.05) and 41 (p less than 0.05), 58% in the NT group, while the corresponding value in the SH group for VF and VT were 17 (p less than 0.001), 33 (p less than 0.01) and 17 (p less than 0.001), 25% (p less than 0.001), respectively. " 03/01/1992 - "We studied the effects of cicletanine, a furopyridine antihypertensive drug, and furosemide, a loop diuretic, on ventricular arrhythmias, such as sustained ventricular fibrillation (VF) and ventricular tachycardia (VT), and myocardial ion content in Langendorff rat hearts subjected to 30 min global ischaemia then 10 min reperfusion. "
4.	Wounds and Injuries (Trauma) 08/01/1991 - "Thus, these data indicate that cicletanine ameliorates the development of hypertension in Dahl-S rats and protects the cardiovascular and renal systems against the injuries seen in the hypertension. " 07/01/1999 - "Cicletanine protects cardiovascular and renal systems against the injuries induced by hypertension, in addition to its lowering of arterial pressure. "
5.	Ventricular Fibrillation 01/01/1988 - "The risk of occlusion-reperfusion ventricular fibrillation was determined according to Cox's solution based on ST segment elevation, thus enabling quantification of the role of cicletanine. " 01/01/1986 - "On the other hand, the incidence of postreperfusion ventricular fibrillation was lower in the cicletanide group (1 of 14 vs. 5 of 9, p = 0.04). " 01/01/1986 - "Cicletanide significantly reduced early (Phase 1a) postischemic ventricular fibrillation (5 of 25 vs. 12 of 25, p = 0.036) but failed to reduce the incidence of global ischemia-induced ventricular fibrillation. " 02/01/1992 - "All cicletanine concentrations reduced the incidence of irreversible ventricular fibrillation (VF) during reperfusion, an effect roughly concentration dependent in the range of 3 x 10(-5)-10(-4) M, whereas nitrendipine had no influence on arrhythmias." 04/01/1991 - "After 30 min of global ischemia, the incidence (total) of ventricular fibrillation (VF) and ventricular tachycardia (VT) was reduced by 2-week pretreatment of the rats with 30 and 100 mg/kg of cicletanine (VF, 33% at 30 mg/kg and 25% at 100 mg/kg vs. 91% in untreated rats; VT, 42% at 30 mg/kg and 42% at 100 mg/kg vs. 100% in untreated rats), while lower doses of cicletanine (3 and 10 mg/kg) failed to reduce the incidence of reperfusion-induced rhythm disturbances. "

Related Drugs and Biologics

1.	cycletanide (cicletanine)
2.	Epoprostenol (Prostacyclin)
3.	Hydrochlorothiazide (Esidrix)
4.	Terfenadine (Seldane)
5.	Cardiac Glycosides
6.	Sodium-Potassium-Exchanging ATPase (Sodium, Potassium ATPase)
7.	Prostaglandins
8.	Indapamide
9.	Glyburide (Glibenclamide)
10.	Adenosine Triphosphate (ATP)

Related Therapies and Procedures

1.	Oral Administration
2.	Ligation
3.	Nephrectomy